Registration Options

Register for the meeting.

Session Time and Location

Date: Wednesday, 04/27/2022

Time: 8:45 AM (view in the schedule)

Room: TBD

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Session Summary

A 2021 report estimates 6.2 million Americans age 65 and older have Alzheimer’s Disease (AD). Estimates predict this population could grow to 13.8 million by 2060 if no medical developments are made to prevent, slow, or cure AD. Furthermore, Alzheimer’s is the 6th leading cause of death in the US; while deaths from stroke, heart disease and HIV decreased between 2000-2019, deaths due to AD increased more than 145%. Currently available treatment options may modestly slow cognitive decline. Several medications are additionally used off label for psychosis and other behavioral and psychological symptoms of dementia; recently the Food and Drug Administration (FDA) rejected an application for one agent (pimavanserin) to receive FDA approval for this indication. More recently, aducanumab was approved using an accelerated process based on reducing amyloid beta plaque, a surrogate marker for AD. This approval has been met with controversy that impacts how AD is treated and may impact FDA approval for other agents in the future.

 

Faculty Information and Disclosures

Learning Objectives

  1. Describe current options for the treatment of Alzheimer’s Disease.
  2. Discuss the history of drug design focusing on amyloid plaque reduction.
  3. Review data leading to the Food and Drug Administration approval of aducanumab.
  4. Identify the potential use of aducanumab in individualized patient cases.

Continuing Education Credit and Disclosures

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.